THE PRESENT APPLICATION DESCRIBES ANTIBODY FORMULATIONS, INCLUDING MONOCLONAL ANTIBODIES FORMULATED IN HISTIDINE-ACETATE BUFFER. AS WELL AS A FORMULATION COMPRISING AN ANTIBODY THAT BINDS TO DOMAIN II OF HER2 (FOR EXAMPLE, PERTUZUMAB), AND A FORMULATION COMPRISING AN ANTIBODY THAT BINDS TO DR5 (FOR EXAMPLE, APOMAB).